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ABCG2, also known as BCRP, is a high-capacity urate exporter, the dysfunction of which raises 
gout/hyperuricemia risk. Generally, hyperuricemia has been classified into urate ‘overproduction 
type’ and/or ‘underexcretion type’ based solely on renal urate excretion, without considering 
an extra-renal pathway. Here we show that decreased extra-renal urate excretion caused by 
ABCG2 dysfunction is a common mechanism of hyperuricemia. Clinical parameters, including 
urinary urate excretion, are examined in 644 male outpatients with hyperuricemia. Paradoxically, 
ABCG2 export dysfunction significantly increases urinary urate excretion and risk ratio of urate 
overproduction. Abcg2-knockout mice show increased serum uric acid levels and renal urate 
excretion, and decreased intestinal urate excretion. Together with high ABCG2 expression in 
extra-renal tissues, our data suggest that the ‘overproduction type’ in the current concept of 
hyperuricemia be renamed ‘renal overload type’, which consists of two subtypes—‘extra-renal 
urate underexcretion’ and genuine ‘urate overproduction’—providing a new concept valuable 
for the treatment of hyperuricemia and gout. 
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H
yperuricemia induces gout and kidney stones and acceler-
ates the progression of renal and cardiovascular diseases1,2. 
Unlike  other  mammals,  hominoids,  including  humans, 
show high serum uric acid levels (SUAs), because uric acid (urate) 
is the end product in the purine metabolism owing to the lack of 
the urate-degrading enzyme uricase3. It is commonly accepted that 
two-thirds of the urate is excreted from the kidney into urine via 
the ‘renal excretion’ pathway, and the remaining third via the ‘extra-
renal excretion’ pathway, such as gut excretion4,5. Hyperuricemia 
has been clinically classified into the urate ‘overproduction’ type, the 
‘underexcretion’ type, and the ‘combined’ type. This classification is, 
however, based solely on the amount of renal urate excretion and 
urate clearance6–9, and extra-renal excretion, for example, via the 
gut excretion pathway, is not considered.
The kidney has been recognized as a main regulator of SUA and 
renal urate excretion is determined by the balance of the reabsorp-
tion and secretion of urate. Renal urate reabsorption is mainly medi-
ated by two urate transporters; urate transporter 1 (URAT1, also 
known as SLC22A12)10 and glucose transporter 9 (GLUT9, also 
known as SLC2A9 (refs 11–15)). Recent genome-wide association 
studies  of  SUA  identified  the  involvement  of  several  transporter 
genes  including  ATP-binding  cassette  transporter,  sub-family  G, 
member 2 (ABCG2, also known as BCRP16–18). The ABCG2 gene 
locates in a gout-susceptibility locus on chromosome 4q, which was 
previously demonstrated by a genome-wide linkage study of gout19. 
Woodward et al. and our group independently found that ABCG2 
transports urate and shows the reduced urate transport by a half-
functional variant, Q141K (rs2231142)20,21. In addition, ABCG2 has 
been identified as a high-capacity urate exporter that would mediate 
renal and/or extra-renal urate excretion21. We also showed that com-
mon dysfunctional genotype combinations of ABCG2 gene (Q126X 
(rs72552713) and Q141K) are a major cause of gout21.
In this study, we investigated the relationship between ABCG2 
dysfunction  and  urate  excretion  in  hyperuricemia  patients  and 
mouse model. We found that decreased extra-renal urate excretion is   
a common cause of hyperuricemia, which has not been considered   
in the current pathophysiological concept of hyperuricemia.
Results
Renal urate excretion in hyperuricemia patients. We investigated 
the  relationship  between  ABCG2  dysfunction  and  renal  urate 
excretion in hyperuricemia patients in this study. The characteristics 
and genotypes of the participants are summarized in Supplementary 
Tables S1 and S2, respectively. The patients’ types of hyperuricemia 
were determined according to the classification of hyperuricemia 
(Fig. 1), which is based on the patient’s urinary urate excretion 
(UUE) and fractional excretion of urate clearance (urate clearance/
creatinine  clearance  ratio,  FEUA).  The  risk  allele  frequency  of 
Q126X (risk allele, X) and Q141K (risk allele, K), among 644 male 
outpatients with hyperuricemia including 575 gout cases, was 4.1 
and 45.9%, respectively. Those who had Q126X and Q141K variants 
were  8.1  and  71.9%,  respectively,  of  all  patients  (Supplementary 
Table S2). Subsequent haplotype frequency analysis revealed that 
the minor alleles of Q126X and Q141K were in different haplotypes 
(Supplementary Table S3), which indicated that these variants were 
independent risks, as reported previously21. Therefore, we could 
estimate urate export function of ABCG2 by the combination of 
two common variants, non-functional Q126X and half-functional 
Q141K (Supplementary Fig. S1). Patients were then divided into 
four  groups  by  genetically  estimated  ABCG2  function21;  that 
is,  full  function,  3/4  function  (mild  dysfunction),  1/2  function 
(moderate  dysfunction)  and  ≤1/4  function  (severe  dysfunction) 
(Supplementary  Table  S4).  Altogether,  75.6%  of  all  patients  had 
ABCG2 dysfunction.
Figure  2a  shows  the  association  between  ABCG2  function 
and  UUE.  Contrary  to  the  general  understanding  that  ABCG2 
dysfunction leads to decreased renal urate excretion, UUE is sig-
nificantly  increased  by  ABCG2  dysfunction  (P = 3.60×10 − 10). 
Whereas the mean UUE level of patients with full ABCG2 func-
tion  was  24.0 mg h − 1/1.73 m2,  that  of  patients  with  severe  dys-
function  (≤1/4  function)  was  34.3 mg h − 1/1.73 m2,  showing  an 
increase of 42.9%. The frequency of ‘overproduction’ hyperuricemia 
(UUE > 25 mg h − 1/1.73 m2), which consists of overproduction type 
and combined type (Fig. 1), is also increased by ABCG2 dysfunc-
tion;  the  ratio  of  ‘overproduction’  hyperuricemia  was  38.2%  in 
patients with full function, and reached 89.7% in those with severe 
dysfunction (Fig. 2b). Severe ABCG2 dysfunction especially raised 
(Overproduction type)
UUE > 25
and
FEUA ≥ 5.5%
(Combined type)
UUE > 25
and
FEUA < 5.5%
(Underexcretion type)
UUE ≤ 25
and
FEUA < 5.5% 
(Overproduction hyperuricemia)
UUE > 25
Figure 1 | Current classification of hyperuricemia. Classification of 
hyperuricemia is based on uuE and fractional excretion of urate (FEuA). 
In this study, patients were classified as overproduction hyperuricemia, 
when their uuE was over 25.0 mg h − 1/1.73 m2 (600 mg per day/1.73 m2). 
Those who had FEuA under 5.5% were classified as underexcretion 
hyperuricemia. Combined type was classified when their uuE and FEuA 
met the criteria of both overproduction and underexcretion hyperuricemia. 
Patients who met the single criterion of overproduction hyperuricemia, 
excluding combined type, were defined as overproduction type. In addition 
to the types shown in this figure, there is a ‘normal type’ whose uuE is 
≤25 mg h − 1/1.73 m2 and FEuA is ≥5.5%. uuE unit, mg h − 1/1.73 m2.
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Figure 2 | Increase of UUE and the frequency of overproduction 
hyperuricemia by ABCG2 dysfunction. (a) uuE according to each 
ABCG2 function (n = 644). Patients with hyperuricemia were divided 
into four groups by their estimated ABCG2 functions, that is, full 
function, 3/4 function, 1/2 function and ≤1/4 function. uuE showed an 
inverse association with ABCG2 functions (P = 3.60×10 − 10 by simple 
linear regression analysis). All bars show mean ± s.e.m. (b) Frequency 
of ‘overproduction’ hyperuricemia according to each ABCG2 function. 
‘overproduction’ hyperuricemia consists of overproduction type and 
combined type.ARTICLE     
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the risk of ‘overproduction’ hyperuricemia, conferring a risk ratio 
(RR) of 2.35 (95% CI 1.86–2.97; P = 3.32×10 − 7) (Table 1). In addi-
tion, moderate and mild dysfunction also significantly increased the 
risk of ‘overproduction’ hyperuricemia, conferring an RR of 1.66 
(95% CI 1.32–2.10; P = 8.58×10 − 6) and 1.36 (95% CI 1.09–1.71; 
P = 4.55×10 − 3), respectively. Risk of overproduction hyperuricemia 
was still significant after adjustment (Table 1). These results clearly 
demonstrate that ABCG2 dysfunction increases UUE, thereby lead-
ing to increased frequency of ‘overproduction’ hyperuricemia. This 
seems paradoxical in light of the current concept of hyperuricemia, 
but it would be understandable if extra-renal excretion via ABCG2 
has a physiologically significant role in urate regulation.
Abcg2 dysfunction and urate excretion in mice. Next, we inves-
tigated how ABCG2 dysfunction affected the urate excretion path-
ways and re-evaluated the current concept of hyperuricemia based 
on ABCG2 dysfunction. The evaluation of gut urate excretion in 
humans  is  intrinsically  difficult  because  urate  excreted  into  the 
intestinal lumen is rapidly metabolized by bacterial flora. To solve 
this problem, we introduced an animal model in which urate excre-
tion through the gut is easily achievable by invasive sampling. Also, 
Abcg2-knockout mice were treated with oxonate, a uricase inhibitor, 
so that the urate metabolism of this model mimicked that of humans 
that lacks the urate degrading enzyme, uricase22. First, mouse Abcg2 
is revealed to mediate urate transport (Fig. 3a) using the membrane 
vesicle  system  prepared  from  HEK293  cells  that  express  mouse 
Abcg2. The export process by mouse Abcg2 was ATP-dependent 
and not saturable under the physiological concentration of urate 
(Fig. 3a), indicating high-capacity urate transport activity by Abcg2. 
Another  functional  analysis  demonstrated  that  oxonate  has  no 
hazardous effect on the Abcg2-mediated urate transport (Fig. 3b). 
We then tried to characterize the excretion of urate into urine, bile 
and intestinal lumen using the in vivo mouse model. As shown in   
Fig. 3c, SUA of Abcg2-knockout mice was significantly higher than 
that of control mice (P = 8.8×10 − 6), which is consistent with the 
increase  of  SUA  in  humans  with  ABCG2  dysfunction21.  Under 
this condition, the urinary urate/creatinine ratio was significantly 
increased in Abcg2-knockout mice (P = 4.1×10 − 4) (Fig. 3d), which 
also  corroborates  the  observation  in  humans  (Fig.  2a).  On  the 
other hand, the urate excretion from the intestine was significantly   
lower in Abcg2-knockout mice (Fig. 3e), which is supported by the 
similar  results  of  the  transintestinal  urate  transport  experiment 
(Fig. 3f; Supplementary Fig. S2). Calculated velocity of the intestinal 
urate excretion in Abcg2-knockout mice was less than a half of that 
in control mice (P = 3.6×10 − 4) (Fig. 3g), whereas biliary urate excre-
tion showed no significant difference regardless of Abcg2 genotype 
(Fig. 3g). From these results, we estimated the relative contribution 
of each pathway to the total urate excretion; in wild-type mice, the 
UUE pathway contributes approximately two-thirds, and the intes-
tinal  excretion  pathway  contributes  one-third  of  the  total  urate 
excretion, whereas the urate excretion into bile is 2.2% of the total 
urate excretion (Fig. 3h). The ratio of each urate excretion path-
way is consistent with the previous literature about the estimation 
of urate excretion pathways in humans4,5. As a result of decreased 
intestinal excretion, the urate excretion in Abcg2-knockout mice was 
much more dependent on the urinary excretion pathway (Fig. 3h). 
Furthermore, the small contribution of biliary urate excretion in 
mice (Fig. 3h) is also consistent with a report of human urate excre-
tion, which shows that biliary urate excretion consists of less than   
5 percent of the total urate excretion23. Taken together, ABCG2 
is suggested to have an important role in extra-renal urate excre-
tion, especially in intestinal urate excretion. Accordingly, increased 
SUA in patients with ABCG2 dysfunction can be explained by the 
decreased excretion of urate from the intestine.
Discussion
We found that the decrease in urate exporter ABCG2 function in 
hyperuricemic patients is associated with the increase of UUE and 
frequency of overproduction hyperuricemia, which consists of the 
overproduction type and the combined type. Also, any ABCG2 dys-
function  caused  by  common  dysfunctional  variants  significantly 
raised the risk of overproduction hyperuricemia. Abcg2-knockout 
mice treated with oxonate showed increased renal urate excretion as 
well as SUA and decreased intestinal urate excretion, compared with 
those of wild-type mice. These findings indicate that the decrease in 
extra-renal urate excretion via dysfunctional ABCG2 is a common 
mechanism of hyperuricemia, which has been currently mistaken 
for urate ‘overproduction’ due to increased UUE.
Three main transporters have been confirmed to regulate SUA 
in humans; a secretion transporter ABCG2 and two urate reabsorp-
tion transporters, URAT1 (ref. 10) and GLUT9 (refs 14,15). In addi-
tion, urate transporters including ABCG2 and URAT1 are regulated 
Table 1 | Relationship between overproduction hyperuricemia and ABCG2 dysfunction.
Estimated 
transport 
activity
Genotype N Frequency  
of OP  
hyper- 
uricemia
RR 95% CI P Adjusted 
RR†
Adjusted 
95% CI†
Adjusted 
P†
Q126X 
(rs72552713)
Q141K 
(rs2231142)
OP hyper-
uricemia*
Non-OP  
hyper-
uricemia*
≤1/4 
Function
X/X Q/Q 26 3 0.897 2.35 1.86–2.97 3.32×10 − 7 2.30 1.31–3.90 2.65×10 − 3
Q/X Q/K
1/2 
Function
Q/X Q/Q 96 55 0.636 1.66 1.32–2.10 8.58×10 − 6 1.79 1.25–2.59 1.55×10 − 3
Q/Q K/K
3/4 
Function
Q/Q Q/K 160 147 0.521 1.36 1.09–1.71 4.55×10 − 3 1.42 1.03–2.00 0.035
Full 
function
Q/Q Q/Q 60 97 0.382 1.00
Abbreviations: CI, confidence interval; oP, overproduction; RR, risk ratio.
*Patients were classified as oP hyperuricemia (oP type and combined type) when their uuE was over 25.0 mg h − 1/1.73 m2 (600 mg per day/1.73 m2).
uuE was normalized for a body surface area of 1.73 m2. other patients were classified as non-oP hyperuricemia.
†using Poisson regression analysis, RR, 95% CI, and P value are adjusted with covariates of body mass index, alcohol intake, and single nucleotide polymorphisms of urate-related genes (rs506338 in 
URAT1, rs11722228 in GLUT9 and rs12129861 in PDZK1).ARTICLE
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by an adaptor protein, the PDZ domain containing-protein, PDZK1 
(refs 24,25). Among these urate-related genes, dysfunctional vari-
ants of ABCG2 are demonstrated as a major cause of gout and hype-
ruricemia20,21.  ABCG2  is  expressed  on  the  apical  membrane  of   
several tissues including kidney26, liver and intestine27. As ABCG2 
is  supposed  to  mediate  renal  urate  excretion20,  the  dysfunction 
of this molecule is expected to decrease UUE. The results in this 
study, however, show an opposite conclusion that the dysfunction 
of ABCG2 results in an increase of UUE. This contradiction can 
be explained by two facts: kidney is not the only organ in which 
ABCG2 is expressed27,28, and one-third of urate excretion in humans 
depends on the extra-renal pathway such as gut excretion4,5,8. Also, 
together with little intestinal expression of URAT1 (ref. 10), our 
data from an animal model indicate that the decreased expression 
of Urat1 in the kidney could partially account for the increased 
urate in urine in Abcg2-knockout mice (Fig. 3d, Supplementary   
Fig. S3). Therefore, it is reasonable that common dysfunction of 
ABCG2 can cause a decrease of urate excretion via the extra-renal 
pathway rather than the renal pathway.
The  current  classification  of  hyperuricemia  is  based  on  the 
understanding of its mechanism by which hyperuricemia results 
from either overproduction of urate due to a metabolism disorder, 
underexcretion by abnormal renal urate transport activity, or the 
combination of the two. So far ‘renal urate underexcretion’ has been 
widely considered to be a main cause of hyperuricemia, and ‘urate 
overproduction’ is recognized as another common cause. A part 
of hyperuricemia is definitely attributable to lifestyle factors such 
as consumption of an excessive amount of alcohol as well as high- 
calorie diet intake. However, even taking such factors into account, 
most  causes  of  ‘overproduction’  hyperuricemia  still  cannot  be 
explained. Many attempts have been made to elucidate the patho-
genesis of ‘overproduction’ hyperuricemia. Nevertheless, no study 
has succeeded in identifying the exact mechanism of urate over-
production  except  some  urate  metabolism  disorders29  including 
Lesch–Nyhan  syndrome  (hypoxanthine-guanine  phosphoribosyl 
transferase deficiency), accelerated purine nucleotide degradation 
and accelerated ATP breakdown. Our findings indicate that a major 
cause of ‘overproduction’ hyperuricemia is not true overproduction 
of urate but rather ‘extra-renal urate underexcretion’ by common 
ABCG2 dysfunction. We also suggest that re-classification of hyper-
uricemia is necessary because ‘overproduction’ hyperuricemia in the 
current classification is only defined by the result of UUE value and 
does not represent a correct pathophysiological condition. There-
fore, our data lend support to the idea that ‘overproduction type’ 
in the current classification of hyperuricemia should be renamed 
‘renal overload type,’ which includes subtypes of ‘extra-renal under-
excretion’ and genuine ‘overproduction’ (Fig. 4).
In this study, we suggest a common mechanism of hyperuricemia 
by  decreased  extra-renal  excretion  due  to  ABCG2  dysfunction. 
Therefore, ABCG2 could be a promising target for urate-lowering 
medications without adverse effects such as urolithiasis. Our find-
ings and proposal would serve to correct the long-misunderstood 
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pathophysiology  of  hyperuricemia.  This  new  concept  will  help 
pinpoint the causes of hyperuricemia more accurately and provide 
a more effective therapeutic strategy for hyperuricemia and gout, 
leading to a good model of personalized medicine for common   
diseases.
Methods
Study participants. This study was approved by the institutional ethical commit-
tees, and all procedures involved in this study were performed in accordance with 
the Declaration of Helsinki. Hyperuricemia patients were diagnosed when their 
SUAs were higher than 7.0 mg dl − 1, and gout cases were also clinically diagnosed 
as primary gout according to the criteria established by the American College of 
Rheumatology30. All hyperuricemic subjects and primary gouty patients were eligi-
ble, when written consent was obtained at the gout clinics of either Jikei University 
Hospital (Tokyo, Japan) or Midorigaoka Hospital (Osaka, Japan). The following 
patients were excluded; patients without information on clinical parameters shown 
in Supplementary Table S1, or those with inherited metabolism disorders including 
Lesch–Nyhan syndrome. Finally, 644 male outpatients, including 575 gout cases, 
were registered as valid participants.
Clinical parameters for urate handling. Clinical parameters including SUA, 
amount of UUE and fractional excretion of urate clearance (urate clearance/
creatinine clearance ratio, FEUA) were measured for each patient after diet 
education, concerning low-purine and calorie-controlled diet, as well as less 
fructose and alcohol intake31,32. Clinical parameters before taking medications for 
hyperuricemia were used in this study. Both UUE and FEUA were calculated after a 
few-hour urine collection. UUE was normalized for a body surface area of 1.73 m2. 
In this study, patients were classified as overproduction hyperuricemia when their 
UUE was over 25.0 mg h − 1/1.73 m2 (600 mg day − 1/1.73 m2)7,8,33. Those who had 
FEUA under 5.5% were classified as underexcretion hyperuricemia34 on the basis 
of the normal FEUA range (5.5–11.1%)35. Combined type was classified when 
their UUE and FEUA met the criteria of both overproduction and underexcretion 
hyperuricemia (Fig. 1). Patients who met the single criterion of overproduction 
hyperuricemia, excluding combined type, were defined as overproduction type.
Genetic analysis. Genomic DNA was extracted from whole peripheral blood 
cells36. Genotyping was performed by high-resolution melting analysis with a 
LightCycler 480 (Roche Diagnostics)21, or by an allelic discrimination assay  
(Custom Taqman MGB, Applied Biosystems) with a 7700 detector (Applied  
Biosystems)37. To confirm their genotypes, more than 100 samples were subjected 
to direct sequencing with primers shown in Supplementary Table S5. DNA  
sequencing analysis was performed with a 3130×l Genetic Analyzer (Applied  
Biosystems)21. The export function of ABCG2 was then estimated from the  
combinations of ABCG2 variants, rs72552713 (Q126X) and rs2231142 (Q141K), 
and divided into four functional groups21; that is, full function, 3/4 function  
(mild dysfunction), 1/2 function (moderate dysfunction) and ≤1/4 function  
(severe dysfunction).
Experimental assessment for urate excretion pathways. Mouse Abcg2 
complementary DNA (GenBank accession number NM_011920) was inserted 
into the Not I site of pcDNA3.1( + ) vector plasmid (Invitrogen), with a myc-tag 
sequence attached at the 5′-end. The wild-type human ABCG2 cDNA (GenBank 
accession number NM_004827) or mutated (Q126X and Q141K) ABCG2 cDNA 
was inserted into the Nhe I and Apa I sites of pcDNA3.1( + ) vector plasmid, with a 
myc-tag sequence attached at the 5′-end21. To prepare membrane vesicles, HEK293 
cells were transiently transfected with the expression vector for Abcg2/ABCG2 
or empty vector (control) by FuGENE6 (Roche Diagnostics), according to the 
manufacturer’s instructions. Forty-eight hours later, cells were collected and the 
membrane vesicles were isolated by a standard method with repeated centrifuga-
tion and homogenization38. After the expression of Abcg2 protein was confirmed 
by western blot analysis, the uptake studies of [14C]urate (28 µM, American  
Radiolabeled Chemicals) were performed by a standard protocol for transport  
assays with membrane vesicles39. All other chemicals used in this study were  
commercially available and of reagent-grade.
Male Abcg2-knockout mice (FVB.129P2-Abcg2, Taconic) and control FVB 
mice of 27–33 g were fed 2.0% (w/w) potassium oxonate for more than 1 week, as 
reported earlier40. Concentrations of urate and creatinine in collected serum and 
urine samples were determined by QuantiChrom Uric Acid Assay Kit (Bioassay 
systems) and Creatinine Assay Kit (Cayman Chemical Company). To analyze the 
intestinal urate excretion, mice fasted-overnight were anaesthetized by intraperito-
neal injection of urethane and cannulated with polyethylene tubing (Hibiki Size 8) 
(Kunii Co.) at the upper duodenum and the middle jejunum to make an intestinal 
loop at the upper half of the intestine. After the intestinal contents were removed 
by the slow infusion of saline and air, the efflux buffer (saline containing 0.3 mM 
potassium oxonate) was introduced into the intestinal loop, and both ends of the 
loop were closed with syringes. After the indicated periods, the efflux buffer in the 
loop was collected by syringes and urate concentrations were quantified. Intestinal 
urate excretion was calculated from the following equation:
[ ] [ Intestinalurateexcretion Urateconcentrationintheintesti = n nalloop
Volumeofeffluxbufferintheintestinalloop
Lengt
]
[ ]
[
×
× h hof thewholesmallintestine
Lengthof theintestinalloop
]
/[ ]
To investigate the biliary urate excretion, mice were anaesthetized by intraperi-
toneal injection of urethane, the cystic duct was ligated and a common bile duct 
fistula was created using a Teflon catheter (UT-03) (Unique Medical). Urate in the 
hepatic bile specimens collected for 3 h was examined. Relative contribution of 
urinary, intestinal and biliary excretion pathways was estimated by the comparison 
of the calculated velocity of each pathway, for which the amount of daily urine is 
assumed to be 2 millilitres. Protocols were performed according to accepted crite-
ria for humane care of experimental animals and approved by the review board of 
our institution for animal studies.
Western blot analysis. For western blot analysis, 5 µg of membrane vesicles 
diluted with 2×SDS loading buffer was separated on a 10% SDS-polyacrylamide  
gel electrophoresis plate with a 3.75% stacking gel. Proteins were transferred 
electrophoretically onto an Immunobilon membrane (Millipore) using a blotter 
(Bio-Rad Laboratories) at 15 V for 1 h. The membrane was blocked with Tris-
buffered saline containing 0.05% Tween 20 (TBS-T) and 3% bovine serum albumin 
(BSA) for 1 h at room temperature. After washing with TBS-T, the membrane 
was incubated for 1 h at room temperature in TBS-T containing 0.1% BSA and 
anti-ABCG2/BCRP antibody (BXP-53, Abcam) (1:500, 0.5 µg ml − 1) for the detec-
tion of ABCG2, or anti-Na + /K + -ATPase α antibody (Santa Cruz Biotechnology) 
(1:200, 1.0 µg ml − 1) as a loading control of membrane proteins. For detection, the 
membrane was allowed to bind to a horseradish peroxidase-labelled secondary 
antibody (GE Healthcare) diluted 5,000-fold in TBS-T containing 0.1% BSA for 
1 h at room temperature. The enzyme activity was assessed using an ECL Prime 
Western Blotting Detection System (GE Healthcare) with a luminescent image 
analyzer (Bio-Rad).
Transintestinal urate transport experiment. To demonstrate the intestinal trans-
port of urate, the upper third of mice intestine specimens was collected and enteral 
contents were carefully removed. Next, both ends of the specimens were connected 
with syringes and the luminal sides were filled with 5 ml of Ringer Buffer (93.4 mM 
NaCl, 6.2 mM KCl, 2.0 mM KH2PO4, 1.2 mM MgSO4-7H2O, 2.5 mM CaCl2-2H2O, 
pH 7.4, 37 °C). Then, the specimens were incubated with [14C]urate (0.4 µM)-con-
taining Ringer Buffer (pH 7.4, 37 °C), pre-bubbled with mixed gas (95% O2 and 5% 
CO2) for 30 min. After incubation with indicated periods, 200 µl of luminal buffer 
was sampled followed by the addition of the same aliquot of the buffer. Syringes 
A: Overproduction type
B: Renal underexcretion type
A: Renal overload type
A1: Overproduction type
A2: Extra-renal underexcretion type
(mostly ABCG2 dysfunction)
B: Renal underexcretion type
A1
A B B
A2
Combined type Combined type
Current classification
B
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Uric acid
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Figure 4 | Pathophysiological model and proposed new classification 
of hyperuricemia. Hyperuricemia is currently classified into urate 
‘overproduction type’ (A), ‘renal underexcretion type’ (B), and combined 
type. Taking extra-renal urate excretion into account, we propose a 
testable model by which ‘overproduction type’ be renamed ‘renal overload 
type’ (A), consisting of two subtypes, genuine ‘overproduction’ (A1) and 
‘extra-renal underexcretion’ (A2).ARTICLE
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were slowly pumped every 2.5 min to thoroughly mix the luminal buffer  
(Supplementary Fig. S2).
Quantitative real-time PCR. To determine messenger RNA levels of genes  
involved in urate transport, mice kidney specimens were homogenized in RNA  
iso plus (Takara) and extracted RNA was reverse-transcribed with ReverTra Ace 
(Toyobo). Quantitative real-time PCR was performed using 2× SYBR GREEN 
(Stratagene) and Chromo4 (BIO-RAD) at 95 °C 10 min followed by 40 cycles at 
95 °C for 15 s, 50 °C for 30 s, and 72 °C for 40 s. We used primers for Abcg2 (sense 
and antisense primers were 5′-aagcatagggatggagctga-3′ and 5′-ctgtgcttgagtc 
caaacca-3′, respectively), Urat1 (sense and antisense primers were 5′-atcatctccatgct 
gtgctg-3′ and 5′-aagtccacaatcccgatgag-3′, respectively), Glut9 (sense and antisense 
primers were 5′-cggcctggctctcaaacttcgccg-3′ and 5′-ggcgaagacgaggaagcagt-3′,  
respectively), Pdzk1 (sense and antisense primers were 5′-atataatgcctcagggcgtg-3′ 
and 5′-atggctggcgttctctacat-3′, respectively) and β-actin (sense and antisense prim-
ers were 5′-ccggaaggaaaactgacagc-3′ and 5′-gtggtggtgaagctgtagcc-3′, respectively).
Statistical analysis. Haplotype estimation was performed with the EM algo-
rithm41. To investigate the association of ABCG2 functions and UUE, simple 
linear regression analysis was performed with UUE as a dependent variable and 
estimated function of ABCG2 as an independent variable. To evaluate the relation-
ship between ABCG2 function and overproduction hyperuricemia, the risk ratio 
(RR) and its 95% CI were calculated by dividing the proportion of overproduction 
hyperuricemia in each function category by that in full function category. Poisson 
regression analysis was performed to obtain adjusted RR of ABCG2 dysfunction 
for overproduction hyperuricemia with possible confounding factors, such as 
body mass index, alcohol intake, single nucleotide polymorphisms of urate-related 
genes, rs11722228 (GLUT9/SLC2A9)18, rs506338 (URAT1/SLC22A12)18, and 
rs12129861(PDZK1)17. For all calculations in the statistical analysis, software R 
(version 2.8.1) (http://www.r-project.org/) and SPSS (version 16.0J for Windows) 
(SPSS) were used. 
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